Matrix metalloproteinases (MMPs) are calcium-dependent zinc containing endopeptidases responsible for the degradation of most of extracellular matrix proteins during organogenesis, growth and normal tissue turnover. MMPs play a role in almost every biological cell process from embryo implantation to cell death and have been implicated in a wide range of diseases including inflammation, arthritis, pulmonary disease, cancer and more.
PerkinElmer’s MMPSense NIR activatable fluorescence agents are designed to evaluate many disease related processes including cancer progression, rheumatoid arthritis, pulmonary disease and more as well as evaluating therapeutic efficacy of potential drug candidates.
Item(s) added to cart.
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
MMPSense 645 FAST is excited by 649 nm excitation light, and emits at 666 nm. MMPSense 645 FAST is a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that allows for an earlier optimal imaging window of 6-24 hours after injection, facilitating detection of early MMP activity changes, for example in acute models of inflammation or stroke. Including MMPSense 645 FAST in careful experimental design allows for multiplexing with other channels and/or imaging times, and so can be paired with other probes to achieve maximum efficiency and flexibility in imaging.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||MMPSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||645 nm|
MMPSense 645 FAST a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.